These findings position MCC950 and OLT1177 as leading inhibitors in the control of NLRP3 inflammasome activation, with potential applications in inflammatory, neurodegenerative, and autoimmune diseases, including sepsis and secondary neurological damage (Table 1) (43, 48, 49). This evidence concerns the gene NLRP3 and Sepsis.